Tools for diagnostics and drug development in cancer

The project "CanCure: Tools for diagnostics and drug development in cancer"  is run by a consortium at Uppsala University, lead by professor Ulf Landegren. The project is funded by Stiftelsen för Strategisk Forskning (The Swedish Foundation for Strategic Research) as part of their program "Design, development and validation of new predictive models and new biomarkers necessary for development of new drugs"

In the CanCure project, we will exploit a unique set of technologies, reagents, samples, and clinical expertise to develop and apply a new generation of protein analytic tools and markers for drug development and drug response prediction with a focus on colorectal cancer (CRC). We will develop proximity ligation assays capable of measuring protein-protein interactions and post-translational modifications to analyze key protein nodes of these molecular pathways using a vast resource of antibodies.

In parallel, we will take advantage of knowledge of molecular pathways frequently mutated in CRC to construct human cell lines with specific mutations on a common genetic background by homologous recombination. The assays, markers, and cell lines will jointly enable sensitive and specific multiplex in situ measurements of cancer gene and pathway activity in cell cultures and in patient tissue samples.

This will allow us to screen chemical libraries in search for new drug lead compounds, and to establish predictive tests for therapy selection, making good use of extensive sample collections established by the partners for first-step validation.

The project is expected to result in cell lines valuable for drug screening, and high-performance protein assays and novel markers for research, clinical applications and drug development. We also anticipate identifying lead compounds and novel drug targets for CRC therapy.